摘要 |
FIELD: medicine.SUBSTANCE: to treat heart failure in individual, receiving anticoagulant therapy introduced are: a) pharmaceutical composition, including therapeutically effective quantity of trisodium [3-((1S,3R)-1-diphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3?-methyl-2?-(pentanoyl-{2?-(tetrazol-5-ylate)diphenyl-4?-ylmethyl}amino)butirate]semi-pentahydrate and pharmaceutically acceptable carrier or b) pharmaceutical composition, including therapeutically effective quantity of (i) valsartan or its pharmaceutically acceptable salt; (ii) ethyl ester of N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid or 2R,4S)-5-diphenyl-4-yl-4-(3-carboxypropyonylamino)2-methylpentanoic acid or its pharmaceutically acceptable salt; and (iii) pharmaceutically acceptable carrier.EFFECT: method makes it possible to increase treatment efficiency with absence of pharmacokinetic or pharmacodynamic interaction with warfarin.6 cl, 4 dwg, 3 tbl |